IDEAYA Biosciences
$19.019876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$19.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.43 (-2.21%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell IDYA and other stocks, options, and ETFs commission-free!
About IDYA
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA. The listed name for IDYA is IDEAYA Biosciences, Inc. Common Stock.
CEO
Yujiro S. Hata
Employees
47
Headquarters
South San Francisco, California
Founded
2015
Market Cap
552.62M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
474.99K
High Today
$20.75
Low Today
$18.61
Open Price
$19.46
Volume
298.40K
52 Week High
$20.75
52 Week Low
$2.95
Collections
Analyst Ratings
100%
of 8 ratings
Buy
100%
Hold
0%
Sell
0%
IDYA Earnings
-$1.30
-$0.87
-$0.43
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 24, Pre-Market